CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗急性淋巴细胞白血病的临床应用
英文原题：Clinical use of CAR T-cells in treating acute lymphoblastic leukemia.
查看英文原题
Clinical use of CAR T-cells in treating acute lymphoblastic leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法改变了成人复发/难治性B细胞急性淋巴细胞白血病（R/R B-ALL）的治疗格局。然而，与R/R B-ALL相比，CAR-T 细胞治疗R/R T-ALL面临独特挑战，例如缺乏特异性肿瘤抗原、T细胞同类相残和T细胞缺失。尽管CAR-T 治疗R/R B-ALL已取得令人鼓舞的疗效，但其应用仍受高复发率和免疫毒性限制。近期研究提示，CAR-T 治疗后接受异基因造血干细胞移植的患者可能获得持久缓解并改善生存，但这一做法仍存在争议。本文简要综述CAR-T 细胞临床治疗ALL的已发表数据。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
However CAR T-cell therapy of R/R T-ALL has unique challenges, such as the lack of specific tumor antigens, cell fratricide and T cell aplasia, in comparison with that of R/R B-ALL. Despite promising therapeutic outcomes in R/R B-ALL, application of this therapy is limited by high relapse rates and immunological toxicities. Recent studies suggest patients who underwent allogeneic hematopoietic stem cell transplantation post-CAR T-cell therapy would achieve durable remission and better survival, but this remains controversial.
Herein, I briefly review published data on the clinical use of CAR T-cells in treating ALL.
论文信息
- 作者
- Korkmaz S
- 单位
- University of Health Sciences, Kayseri Faculty of Medicine, Department of Hematology, Apheresis & BMT Unit, Kayseri, Turkey. Electronic address: baranserdalkorkmaz@gmail.com.Turkey
- 文献类型
- 综述
- 期刊
- Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2023 Apr
- 原文标识
- PubMed 36868895 · DOI 10.1016/j.transci.2023.103666